Additional exploratory analysis measuring quality of life, anxiety and depression assessments was next analyzed to evaluate how CYP2D6/CYP2C19-C and CYP2D6/CYP2C19-I subgroups changed over the course of treatment. The gene discussed is CYP2D6; the disease is depressive symptom measurement.